NRSNW
NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. (NRSNW) is currently in a downtrend, trading below both the 50-day and 200-day moving averages. RSI is at 48.3, with 0/3 trend checks passing.
NRSNW with MA50 and MA200
Key levels & signals
NeuroSense Therapeutics Ltd. (NRSNW) currently looks weaker on the chart and is not showing much trend strength. The latest available price is $0.12, and 0 of 3 core trend checks are currently passing. Price is trading below the 50-day moving average by 25.8% and below the 200-day moving average by 62.0%.
NRSNW currently has an RSI reading of 48.3, which sits in a neutral range. That usually means momentum is not especially stretched in either direction, so traders may need to rely more on chart structure than on oscillator extremes alone.
For traders reviewing NRSNW next, the main question is whether weakness is starting to stabilise or whether the chart still looks vulnerable to further downside. Some traders may watch for bounce attempts, but others will want to see stronger proof that the trend is improving before treating the stock as a cleaner setup.
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS). Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.
NRSNW shares outstanding over time
Tracking total shares outstanding is one way to spot dilution — a rising line means the company has issued more shares (stock-based compensation, secondary offerings, convertible debt), which spreads the same earnings and ownership across more shares. A falling line usually reflects buybacks.
Learn the indicators behind this page
More stock opportunities
Common questions about NRSNW
Is this page a buy or sell recommendation?
No. This page is designed to help you review chart structure, momentum and technical context more quickly, but it is not personal financial advice.
Why can a stock look bullish and overbought at the same time?
Strong trending stocks can still become stretched in the short term. That is why trend traders and dip buyers can read the same chart differently.
What should I do next after reading this page?
Open the full dashboard, review the chart in more detail, compare indicators, and decide whether the setup still makes sense within your own process.